Ewa Wajs, MD, PhD

Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients With Treatment-Resistant Depression in SUSTAIN-2 (NCT02497287)

We assessed potential withdrawal symptoms in patients with treatment-resistant depression (TRD) after long-term, intermittent use of intranasal esketamine (ESK). Patients received ESK 2X/...

Allitia DiBernardo , MD;

Ewa Wajs , MD, PhD;

Andrew Krystal , MD;

Lynn Yieh , PhD;

Ella Daly , MB, BCh, BAO;

Leah Aluisio , PhD;

Wayne Drevets , MD;

Yun Wu , PhD;

Jaskaran Singh , MD;

Peter Zannikos , PhD;

Jagadish Gogate , PhD;

Valerie Curran , PhD;

Guang Chen , MD, PhD;

11/22/2019

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results From the Clinical Development Program

Aim: To evaluate the cardiac safety of esketamine nasal spray administered to patients with treatment-resistant depression (TRD). Methods: Cardiovascular (CV) effects of esketamine nasal...

Jaskaran Singh , MD;

Teodora Doherty , MD;

Michael Weber , MD, PhD;

Ewa Wajs , MD, PhD;

Rama Melkote , MSc, MPH;

Janice Miller , MD;

11/22/2019